In brief
Sue Desmond-Hellmann argues that she became a biotech leader by combining two viewpoints: the physician who cares about one patient, and the public health thinker who cares about whole populations. Her path ran from a strict Catholic family in Reno through the AIDS epidemic in San Francisco and Uganda to drug development at Bristol-Myers Squibb and Genentech. She credits steady, practical contribution over polish.
The main arc is her move from treating patients one at a time to helping many patients through medicines. She first resisted leaving practice, kept her license as a backup, and then found industry fit her skills in statistics, safety, regulation and teamwork. At Genentech she helped build clinical capability around a strong research culture, while fast growth strained hiring and management.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Sue Desmond-Hellmann worked at Genentech from 1995 to 2009, a period the host describes as its glory days as a developer of cancer drugs.
“She made her name in the biopharmaceutical industry at Genentech from 1995 to 2009, the glory days when it became the world's most important developer of new cancer drugs.”
0:00:01 · Luke Timmerman · Genentech career · 1995-2009
After leaving Genentech, Sue Desmond-Hellmann became Chancellor of UCSF and then CEO of the Bill and Melinda Gates Foundation until January 2020.
“After Genentech, she served as Chancellor of UCSF and then worked as CEO of the Bill and Melinda Gates Foundation until January of 2020.”
0:00:43 · Luke Timmerman · Career path · 2020
At the time of the interview, Desmond-Hellmann sat on Pfizer's board and advised the venture firm GV, formerly Google Ventures.
“Currently, among other things, Sue is a board member for Pfizer and is an advisor to GV, the venture capital firm formerly known as Google Ventures.”
0:00:43 · Luke Timmerman · Board roles · 2021
Host Luke Timmerman credits Pfizer with helping BioNTech develop an mRNA COVID-19 vaccine in record time with very high efficacy.
“And I really want to give hats off to Pfizer for stepping up and helping BioNTech and developing this mRNA vaccine in record time and incredible efficacy.”
0:03:05 · Luke Timmerman · COVID-19 vaccine · 2020
Desmond-Hellmann's family moved from Napa to Reno when she was one, and her father and a partner opened a privately owned drugstore there.
“my parents moved to Reno. Reno was really small then and really Western and different and a new town. And my dad and his partner opened up a privately owned drugstore.”
0:09:31 · Sue Desmond-Hellmann · Early life
Desmond-Hellmann attended Catholic school for 12 years and describes her parents as extremely strict.
“I went to Catholic school for 12 years. My parents were extremely strict.”
0:10:13 · Sue Desmond-Hellmann · Education
Desmond-Hellmann was the second of seven children, and the youngest was born the summer after she finished high school.
“The youngest in my family was born the summer after I finished high school.”
0:11:55 · Sue Desmond-Hellmann · Family
Desmond-Hellmann attended the University of Nevada for college and medical school while living at home, to keep expenses low.
“A couple miles away from our house. I lived at home and was so close to running out of money by the time medical school was over.”
0:18:15 · Sue Desmond-Hellmann · Education
Working with oncologist Dr. Stephen Hall in Reno during clinical rotations led Desmond-Hellmann to switch from sports medicine to oncology.
“When I started on the clinical rotations, I worked with a physician, Dr. Stephen Hall, an oncologist in Reno.”
0:21:17 · Sue Desmond-Hellmann · Choosing oncology
In 1982 UCSF's internal medicine department accepted a trainee from the University of Nevada for the first time, Desmond-Hellmann.
“UCSF, for the first time ever in their internal medicine department, took a kid from University of Nevada.”
0:27:14 · Sue Desmond-Hellmann · UCSF residency · 1982
AIDS was first described in 1981, and Desmond-Hellmann began internship at UCSF in 1982, as the epidemic hit gay men in San Francisco.
“So HIV AIDS is described in 81. And I hit San Francisco as an intern in 82.”
0:27:55 · Sue Desmond-Hellmann · AIDS epidemic · 1982
Nick Hellman, from the University of Kentucky, trained at UCSF alongside Desmond-Hellmann and became her best friend and later partner.
“UCSF also took another kid from a state school from University of Kentucky, Nick Hellman, who became my best friend as an intern.”
0:28:41 · Sue Desmond-Hellmann · Personal life · 1982
About three years into her training, Desmond-Hellmann moved into the AIDS clinic at UCSF and treated Kaposi's sarcoma patients full time.
“by the time I was three years into my training, I actually moved into the AIDS clinic and started taking care of Kaposi's sarcoma patients full time.”
0:29:29 · Sue Desmond-Hellmann · Kaposi's sarcoma · 1980s
Kaposi's sarcoma had previously been a rare cancer in elderly Mediterranean men, but in AIDS patients with low CD4 cells it showed how the immune system fights off cancer.
“But here, as these patients had low CD4 cells and immune systems that weren't right, some came with pneumocystis cariniae pneumonia or fungal infections or other infectious diseases, but some presented with Kaposi sarcoma.”
0:30:34 · Sue Desmond-Hellmann · Immune system and cancer · 1980s
Desmond-Hellmann and Nick Hellman went to Uganda on a Rockefeller Foundation-funded project to study heterosexual HIV transmission.
“Nick and I went to study heterosexual transmission of HIV in a Rockefeller Foundation-funded project during the AIDS epidemic.”
0:33:04 · Sue Desmond-Hellmann · Uganda research · 1980s
After returning from Uganda, Desmond-Hellmann practiced as an oncologist for about two years and passed her oncology boards.
“As I like to say now, I was a real doctor for two years, a practicing oncologist. I took my boards, passed my oncology boards.”
0:37:41 · Sue Desmond-Hellmann · Clinical practice
Nick Hellman was recruited to Bristol-Myers Squibb to work on an early antiretroviral drug, which took the couple to Connecticut.
“And then Nick got recruited to Bristol-Myers Squibb to work on D14, one of the first antiretroviral drugs.”
0:37:41 · Sue Desmond-Hellmann · Move to industry
When Desmond-Hellmann joined in the mid-1990s, Genentech had three approved drugs: growth hormone, Activase and Pulmozyme, and no cancer drugs.
“Genentech had three approved drugs, growth hormone, Activase, and Pulmozyme.”
0:41:42 · Sue Desmond-Hellmann · Genentech products · 1995
Desmond-Hellmann notes Genentech was founded in 1976 and that she arrived almost 20 years later.
“And the fact was that Genentech was founded in 76. So I got there, you know, almost 20 years later.”
0:44:51 · Sue Desmond-Hellmann · Genentech history · 1976
Genentech's partnership with IDEC on Rituxan came around 1995 or 1996, and Rituxan was approved in 1997.
“There was not. The partnership came, I think, in 95, 96, because Rituxan was approved in 97.”
0:45:56 · Sue Desmond-Hellmann · Rituxan · 1997
Herceptin was approved in 1998, about a year after Rituxan.
“And then Herceptin came just a year later, I think, 98.”
0:46:04 · Luke Timmerman · Herceptin · 1998
Desmond-Hellmann says Genentech worked with IDEC on Rituxan's approval, and that Herceptin was harder because a diagnostic test had to be approved along with the drug.
“with IDEC, with Antonio Rio Lopez, we worked on the approval of Rituxan, which was hard, but then Herceptin, which was massively hard because we had to get the therapeutic and the diagnostic.”
0:46:33 · Sue Desmond-Hellmann · Cancer antibodies · 1990s
Genentech's R&D head Art Levinson believed in leaving a job open rather than hiring a 'B minus', which made rapid growth harder.
“Art had this philosophy that if you couldn't find the right person for the job, you should just leave it open.”
0:48:54 · Sue Desmond-Hellmann · Hiring philosophy
Desmond-Hellmann says she vividly remembers the day Herceptin was approved and thinking of the women it would help.
“I tell people that when the day that Herceptin was approved, I still remember like it was yesterday.”
0:56:41 · Sue Desmond-Hellmann · Herceptin approval · 1998